Vor Biopharma Inc. (VOR) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -147.08M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 76.85M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-147.08M | (m) | (m) | $76.85M | (m) | (m) |
| 2026-03-31 | $-373.51M | (m) | (m) | $312.43M | (m) | (m) |
| 2025-12-31 | $-371.64M | (m) | (m) | $321.53M | (m) | (m) |
| 2025-09-30 | $-366.99M | (m) | (m) | $327.69M | (m) | (m) |
| 2025-06-30 | $-367.40M | (m) | (m) | $335.37M | (m) | (m) |
| 2025-03-31 | $-122.15M | (m) | (m) | $95.69M | (m) | (m) |
| 2024-12-31 | $-121.19M | (m) | (m) | $93.31M | (m) | (m) |
| 2024-09-30 | $-118.00M | (m) | (m) | $88.86M | (m) | (m) |
| 2024-06-30 | $-124.80M | (m) | (m) | $94.65M | (m) | (m) |
| 2024-03-31 | $-127.94M | (m) | (m) | $96.72M | (m) | (m) |
| 2023-12-31 | $-126.04M | (m) | (m) | $94.31M | (m) | (m) |
| 2023-09-30 | $-122.64M | (m) | (m) | $90.48M | (m) | (m) |
| 2023-06-30 | $-111.42M | (m) | (m) | $79.75M | (m) | (m) |
| 2023-03-31 | $-101.04M | (m) | (m) | $71.19M | (m) | (m) |
| 2022-12-31 | $-93.42M | (m) | (m) | $64.55M | (m) | (m) |
| 2022-09-30 | $-87.00M | (m) | (m) | $60.18M | (m) | (m) |
| 2022-06-30 | $-81.50M | (m) | (m) | $56.23M | (m) | (m) |
| 2022-03-31 | $-78.09M | (m) | (m) | $53.87M | (m) | (m) |
| 2021-12-31 | $-69.02M | (m) | (m) | $47.53M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-43.37M | (m) | (m) | $31.62M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |